Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1960 1
1968 1
1971 1
1978 1
1981 1
1983 1
1984 1
1985 1
1987 1
1988 2
1989 4
1990 3
1991 1
1992 3
1993 3
1994 2
1995 4
1996 1
1997 3
1998 1
1999 8
2000 7
2001 6
2002 4
2003 5
2004 8
2005 7
2006 15
2007 16
2008 5
2009 7
2010 16
2011 16
2012 13
2013 8
2014 6
2015 6
2016 7
2017 7
2018 2
2019 8
2020 9
2021 17
2022 14
2023 6
2024 18
2025 11
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

260 results

Results by year

Filters applied: . Clear all
Page 1
Is That a Real Tumor?
Kondo N, Kasamatsu H, Nakazawa H, Tanaka H, Kuroiwa KK, Ide S. Kondo N, et al. Among authors: kuroiwa kk. J Cardiothorac Vasc Anesth. 2021 Aug;35(8):2530-2532. doi: 10.1053/j.jvca.2021.03.022. Epub 2021 Mar 21. J Cardiothorac Vasc Anesth. 2021. PMID: 33875354 No abstract available.
Primary osteosarcoma of the small intestine.
Yokoyama Y, Nakazawa T, Kanazawa N, Yoshida T, Mitsui H, Kuroiwa K, Honma N, Arai T. Yokoyama Y, et al. Among authors: kuroiwa k. Pathol Int. 2022 Aug;72(8):423-425. doi: 10.1111/pin.13237. Epub 2022 Jun 14. Pathol Int. 2022. PMID: 35698925 No abstract available.
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group. Tanegashima T, et al. Among authors: kuroiwa k. Int J Clin Oncol. 2025 Mar;30(3):551-558. doi: 10.1007/s10147-024-02681-2. Epub 2024 Dec 17. Int J Clin Oncol. 2025. PMID: 39688742
Entanglement Cost for Infinite-Dimensional Physical Systems.
Yamasaki H, Kuroiwa K, Hayden P, Lami L. Yamasaki H, et al. Among authors: kuroiwa k. Commun Math Phys. 2025;406(11):277. doi: 10.1007/s00220-025-05431-1. Epub 2025 Oct 3. Commun Math Phys. 2025. PMID: 41048837 Free PMC article.
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, Wheeler TM, Fine SW, Trachtenberg J, Rubin MA, Ohori M, Kuroiwa K, Rossignol M, Abenhaim L; International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Eggener SE, et al. Among authors: kuroiwa k. J Urol. 2007 Dec;178(6):2260-7. doi: 10.1016/j.juro.2007.08.072. Epub 2007 Oct 15. J Urol. 2007. PMID: 17936815 Review.
Site-specific Response to Nivolumab in Renal Cell Carcinoma.
Negishi T, Furubayashi N, Nakagawa T, Nishiyama N, Kitamura H, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, Okajima E, Nakamura M. Negishi T, et al. Among authors: kuroiwa k. Anticancer Res. 2021 Mar;41(3):1539-1545. doi: 10.21873/anticanres.14913. Anticancer Res. 2021. PMID: 33788747
260 results